Literature DB >> 23943369

Comprehensive assessment of the association between tumor necrosis factor alpha G238A polymorphism and liver cancer risk.

Xin Tian1, Ping Ma, Chengguang Sui, Yan Li, Liye Fu, Tao Jiang, Yang Wang, Youhong Jiang.   

Abstract

Tumor necrosis factor alpha (TNF-α) has been suggested to play an important role in the development and liver cancer. TNF-α 238 G/A polymorphism was hypothesized to increase the risk of liver cancer, but findings from previous studies were controversial. To explore a more precise estimation of the relationship between TNF-α 238 G/A polymorphism and liver cancer, we performed a meta-analysis. PubMed, Embase, and China Biology Medicine databases were searched for all publications on this association through March 12, 2013. Odds ratios (ORs) with its 95% confidence intervals (CIs) were used to assess the strength of this association. Eleven studies with 1,406 liver cancer cases and 2,386 noncancer controls were included into this meta-analysis. Overall, there was a significant association between TNF-α 238 G/A polymorphism and increased risk of liver cancer under all three genetic models (A vs. G, OR 1.51, 95% CI 1.20-1.89, P < 0.001, I(2) = 37.7%; AG vs. GG, OR 1.49, 95% CI 1.01-2.21, P = 0.045, I(2) = 53.2%; AA/AG vs. GG, OR 1.76, 95% CI 1.35-2.30, P < 0.001, I(2) = 36.5%). The sensitivity analysis further strengthened the validity of the positive association. Subgroup analysis of nine studies from Asian countries showed that there was a significant association between TNF-α 238 G/A polymorphism and increased risk of liver cancer in Asians (A vs. G, OR 1.35, 95% CI 1.03-1.76, P = 0.027, I(2) = 40.2%; AA/AG vs. GG, OR 1.56, 95% CI 1.14-2.15, P = 0.006, I(2) = 41.9%). In conclusion, TNF-α 238 G/A polymorphism is significantly associated with increased risk of liver cancer, especially in Asians.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23943369     DOI: 10.1007/s13277-013-1012-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  33 in total

1.  Tumor necrosis factor α -308 G>A polymorphisms and cervical cancer risk: a meta-analysis.

Authors:  Bo Ding; Shilong Fu; Meilin Wang; Cong Yue; Wei Wang; Delan Zhou; Zhengdong Zhang; Suping Han
Journal:  Int J Gynecol Cancer       Date:  2012-02       Impact factor: 3.437

2.  Tumor necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection.

Authors:  Grazia Anna Niro; Rosanna Fontana; Domenica Gioffreda; Maria Rosa Valvano; Angelo Lacobellis; Domenico Facciorusso; Angelo Andriulli
Journal:  Liver Int       Date:  2005-12       Impact factor: 5.828

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

Review 4.  Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.

Authors:  Augusto Villanueva; Beatriz Minguez; Alejandro Forner; Maria Reig; Josep M Llovet
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

5.  Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population.

Authors:  P Kummee; P Tangkijvanich; Y Poovorawan; N Hirankarn
Journal:  J Viral Hepat       Date:  2007-12       Impact factor: 3.728

6.  Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma.

Authors:  Jen-Eing Jeng; Jung-Fa Tsai; Lee-Yea Chuang; Mei-Shang Ho; Zu-Yau Lin; Min-Yuh Hsieh; Shin-Chern Chen; Wan-Lung Chuang; Liang-Yen Wang; Ming-Lung Yu; Chia-Yen Dai; Jan-Gowth Chang
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

Review 7.  Tumour necrosis factor and cancer.

Authors:  Frances Balkwill
Journal:  Nat Rev Cancer       Date:  2009-04-03       Impact factor: 60.716

8.  Independent and additive interactive effects among tumor necrosis factor-alpha polymorphisms, substance use habits, and chronic hepatitis B and hepatitis C virus infection on risk for hepatocellular carcinoma.

Authors:  Jen-Eing Jeng; Huey-Ru Tsai; Lee-Yea Chuang; Jung-Fa Tsai; Zu-Yau Lin; Min-Yuh Hsieh; Shin-Chern Chen; Wan-Lung Chuang; Liang-Yen Wang; Ming-Lung Yu; Chia-Yen Dai; Jan-Gowth Chang
Journal:  Medicine (Baltimore)       Date:  2009-11       Impact factor: 1.889

9.  Tumor necrosis factor alpha -308G>A, -863C>A, -857C>T gene polymorphisms and tuberculosis susceptibility: a meta-analysis.

Authors:  Hang Zhu; Zhijiao Zhang; Xun Lei; Jing Feng; Fan Zhang; Yang Wang
Journal:  Gene       Date:  2012-08-25       Impact factor: 3.688

10.  ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma.

Authors:  Cheng-lin Yang; Feng-qin Jiang; Feng Xu; Gui-xing Jiang
Journal:  Tumour Biol       Date:  2012-05-13
View more
  5 in total

1.  The Potential Role of TNF-α (rs361525 and rs1800629) in Hepatocellular Carcinoma: Multivariate Analysis (Meta-Analysis).

Authors:  Mehdi Heidari Horestani; Golnaz Atri Roozbahani; Masoud Sheidai
Journal:  J Gastrointest Cancer       Date:  2019-12

2.  The Tumor Necrosis Factor-α-308 and -238 Polymorphisms and Risk of Hepatocellular Carcinoma for Asian Populations: A Meta-Analysis.

Authors:  Qing Hu; Guo-Guang Lou; Ying-Chao Liu; Le Qian; Bo-Dong Lv
Journal:  Curr Ther Res Clin Exp       Date:  2014-09-27

3.  Three polymorphisms of tumor necrosis factor-alpha and hepatitis B virus related hepatocellular carcinoma: A meta-analysis.

Authors:  Qi Xiao; BiQi Fu; Ping Chen; Zhong Zhong Liu; Wei Wang; QiFa Ye
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

4.  The ERCC1-4533/8092, TNF-α 238/308 polymorphisms and the risk of hepatocellular carcinoma in Guangxi Zhuang populations of China: Case-control study.

Authors:  Yanqiu Li; Chao Ou; Hong Shu; Huiliu Zhao; Bo Zhu
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

5.  Remarkable Anticancer Activity of Teucrium polium on Hepatocellular Carcinogenic Rats.

Authors:  Ariyo Movahedi; Rusliza Basir; Asmah Rahmat; Mohammad Charaffedine; Fauziah Othman
Journal:  Evid Based Complement Alternat Med       Date:  2014-08-13       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.